Bridgebio Pharma Inc (BBIO)

$35.31

-0.42

(-1.18%)

Market is closed - opens 8 PM, 29 Feb 2024

Insights on Bridgebio Pharma Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 4.09M → 1.74M (in $), with an average decrease of 57.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -176.99M → -168.14M (in $), with an average increase of 5.3% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 243.1% return, outperforming this stock by 292.5%

Performance

  • $35.13
    $36.08
    $35.31
    downward going graph

    0.51%

    Downside

    Day's Volatility :2.64%

    Upside

    2.13%

    downward going graph
  • $10.57
    $44.32
    $35.31
    downward going graph

    70.07%

    Downside

    52 Weeks Volatility :76.15%

    Upside

    20.33%

    downward going graph

Returns

PeriodBridgebio Pharma IncSector (Health Care)Index (Russel 2000)
3 Months
23.89%
13.2%
0.0%
6 Months
24.63%
9.7%
0.0%
1 Year
212.87%
15.4%
-6.7%
3 Years
-50.31%
30.3%
-19.6%

Highlights

Market Capitalization
6.1B
Book Value
- $7.73
Earnings Per Share (EPS)
-3.95
Wall Street Target Price
47.23
Profit Margin
0.0%
Operating Margin TTM
-10123.9%
Return On Assets TTM
-64.08%
Return On Equity TTM
-1789.67%
Revenue TTM
9.3M
Revenue Per Share TTM
0.06
Quarterly Revenue Growth YOY
-6.7%
Gross Profit TTM
74.2M
EBITDA
-593.0M
Diluted Eps TTM
-3.95
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.54
EPS Estimate Next Year
-3.28
EPS Estimate Current Quarter
-0.91
EPS Estimate Next Quarter
-0.83

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Bridgebio Pharma Inc(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
15
15
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 33.76%

Current $35.31
Target $47.23

Technicals Summary

Sell

Neutral

Buy

Bridgebio Pharma Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bridgebio Pharma Inc
Bridgebio Pharma Inc
-5.58%
24.63%
212.87%
-50.31%
29.69%
Moderna, Inc.
Moderna, Inc.
-8.24%
-15.49%
-30.7%
-38.88%
325.66%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.93%
19.55%
30.63%
114.52%
130.61%
Novo Nordisk A/s
Novo Nordisk A/s
12.12%
30.39%
73.39%
235.66%
399.41%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-1.12%
22.56%
48.44%
104.83%
128.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bridgebio Pharma Inc
Bridgebio Pharma Inc
NA
NA
NA
-3.54
-17.9
-0.64
NA
-7.73
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.94
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.21
28.21
2.0
44.85
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
45.17
45.17
4.45
3.31
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.25
31.25
0.59
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bridgebio Pharma Inc
Bridgebio Pharma Inc
Buy
$6.1B
29.69%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$35.9B
325.66%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$107.8B
130.61%
28.21
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$544.3B
399.41%
45.17
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$112.0B
128.3%
31.25
36.68%

Institutional Holdings

  • Kohlberg Kravis Roberts & Co LP

    17.85%
  • Viking Global Investors LP

    14.44%
  • Vanguard Group Inc

    6.48%
  • BlackRock Inc

    5.32%
  • Aisling Capital Management LP

    3.49%
  • LAURION CAPITAL MANAGEMENT LP

    3.25%

Corporate Announcements

  • Bridgebio Pharma Inc Earnings

    Bridgebio Pharma Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.

Organization
Bridgebio Pharma Inc
Employees
0
CEO
Dr. Neil Kumar Ph.D.
Industry
Health Technology

FAQs